$SGHT: Sight Sciences, Inc. - Common Stock

Sight Sciences, Inc. (NASDAQ: SGHT) is a clinical-stage medical technology company focused on the development and commercialization of its proprietary imaging technology for the diagnosis and treatment of eye diseases. The company's lead product candidate, the Guided Image Guided Therapy (GIG) System, is a minimally invasive, image-guided laser therapy system for the treatment of diabetic macular edema (DME).

DME is a leading cause of vision loss in people with diabetes. The disease is caused by the accumulation of fluid and proteins in the macula, a small area of the retina that is responsible for central vision. DME can lead to blurry vision, difficulty reading, and loss of peripheral vision.

The GIG System uses a combination of optical coherence tomography (OCT) and laser therapy to treat DME. OCT is a non-invasive imaging technology that provides detailed images of the retina. The laser therapy component of the GIG System uses a laser to target and remove the excess fluid and proteins that are causing the DME.

Sight Sciences has completed two Phase 3 clinical trials of the GIG System for the treatment of DME. The trials showed that the GIG System was safe and effective, and that it led to significant improvements in vision in patients with DME. Sight Sciences is currently seeking FDA approval for the GIG System.

If approved, the GIG System would be the first image-guided laser therapy system for the treatment of DME. The system has the potential to be a significant improvement over current treatment options for DME, which are often ineffective and can have serious side effects.

In addition to the GIG System, Sight Sciences is also developing other products based on its proprietary imaging technology. These products include a system for the diagnosis of glaucoma, a system for the treatment of retinal tears and detachments, and a system for the treatment of other eye diseases.

Sight Sciences is a promising medical technology company with the potential to make a significant impact on the treatment of eye diseases. The company has a strong management team, a well-funded pipeline of products, and a proprietary technology that has the potential to revolutionize the treatment of these diseases.